Navigation Links
Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program
Date:12/1/2011

xpeditious regulatory review and marketing clearance.

The Company also announced today that the next investor conference call, initially scheduled for late November, will be rescheduled to early January, 2012.  "The Generex management team and its advisors have been working diligently on the previously announced strategic development plan, including the spinout of Antigen Express, the Generex reverse stock split, the stock dividends of Antigen stock to the Generex stockholders, and the clinical and regulatory development programs for Generex Oral-lyn™ and the the AE37 immuno-therapuetic vaccines platform technologies, and significant progress has been made," said Mark Fletcher, the Generex President & Chief Executive Officer.  "In order that the investor conference call will be as productive, informative, and useful as possible, we have elected to reschedule the call to a later date when the plan will have achieved greater maturity and specificity so as to be in a position to provide a more comprehensive and detailed report to our stockholders."

About Generex Biotechnology Corporation

Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device.  Antigen Express, Inc. is a wholly owned subsidiary of Generex.  The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases.  Antigen Express has pioneered the use of specific CD4+ T-helper stimulation in immunotherapy.  One of i
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Generex Makes Podium Presentation of Clinical Data on Generex Oral-lyn™ at European Association for the Study of Diabetes Annual Meeting
2. Generex Provides Update on Spinout of Antigen Express
3. Generex Augments Cash Position With Sales of Non-Essential Assets
4. Amarantus BioSciences and Generex Biotechnology Collaborate on Cell Therapy for Late Stage Diabetes
5. Generex Announces Publication of Studies with the Mayo Clinic Confirming and Extending the Antigen Express Ii-Key Platform Technology
6. Generex Announces U.S. Congressman Curt Weldon, Co-Founder of the Congressional Diabetes Caucus, to Champion Generex Initiatives in Asia and North America
7. Generex Provides Clarification of Facts
8. Generex Announces Results of Annual Stockholders Meeting
9. Generex Announces Publication on Application of Antigen Express Technology for Early Detection of Type 1 Diabetes
10. Generex Oral-lyn™ Data to be Presented at Two International Scientific Symposia
11. Generex Announces Publication of Comparative Peptide Vaccine Studies in Peer Review Journal Demonstrating Superiority of AE37 and Presentation at the American Association for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014  ( www.competitivehealth.com ) — Competitive ... medical bill review and advocacy service, has signed an ... WellCard Savings discount health services marketplace. 63% ... more than they expected to pay. As part of ... costs, WellCard Savings is pleased to offer medical bill ...
(Date:12/22/2014)... 22, 2014 Fertility Associates of Memphis ... Bank USA , a network of more than 20 ... partnership, patients have fast access to a national pool ... IVF . Fertility Associates of Memphis is the only ... treatment option. , Dr. William Kutteh , director ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one ... of Nick Maroulis, Pharm.D. to the newly created position ... In this position, Dr. Maroulis will continue to manage ... of our multi-site pharmacies as the company expands. Dr. ... that time he has served in many different capacities ...
(Date:12/19/2014)... Dec. 19, 2014 Bina Technologies, Inc. (Bina, ... that they have been acquired by Roche (SIX: RO, ... privately held company that provides a big data platform ... (NGS) data for the academic and translational research markets. ... and will continue to focus on development of their ...
Breaking Biology Technology:WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... review demonstrates bioidentical hormones are superior to synthetic ... of breast cancerTORRANCE, Calif., Feb. 23 The ... Postgraduate Medical Journal, a leading peer-reviewed publication for ... with reduced health risks and are more efficacious ...
... - Sirius Genomics, a developer of a pharmacogenomic test ... (sold by Eli Lilly and Company under the trademark ... CEO, will present at the annual Invest Northwest Investor-CEO ... PST. The conference is presented by the Washington Biotechnology ...
... Netherlands, Feb. 23 Schering-Plough Corporation (NYSE: ... between Nobilon, Schering-Plough,s human vaccine business unit, and ... to pandemic influenza vaccine manufacturing technology to developing ... demonstrates Schering-Plough,s strong commitment to innovation and to ...
Cached Biology Technology:New Analysis Finds Bioidentical Hormones Safer Than Standard Hormone Replacement Therapy 2New Analysis Finds Bioidentical Hormones Safer Than Standard Hormone Replacement Therapy 3Sirius Genomics to Present at Invest Northwest Conference 2Schering-Plough Announces Collaboration With World Health Organization to Provide Access to Pandemic Influenza Vaccine Technology to Developing Countries 2Schering-Plough Announces Collaboration With World Health Organization to Provide Access to Pandemic Influenza Vaccine Technology to Developing Countries 3
(Date:12/10/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/xclcvw/biometrics_market ) ... Market in Japan 2014-2018" report to their ... The integration of biometrics and smart ... upgradation of the driver,s license is one of ... the aforementioned projects, biometrics is being used as ...
(Date:12/5/2014)... VIEW, Calif. , Dec. 4, 2014 /PRNewswire/ ... safety has boosted investments in new testing and ... has also given rise to a range of ... by the requirements of Generation Y, which is ... technologies. As a result, product development strategies of ...
(Date:12/4/2014)... BEACH GARDENS, Fla. , Dec. 3, 2014 ... management solutions, today announced that its DigitalPersona ® ... 4500 fingerprint readers have been deployed throughout First ... , South Carolina ... headquartered in Southern Pines, North Carolina ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3
... and water experts have converged at Nanyang Technological University ... research community on a scarce natural resource -- water. ... in the last fortnight as they attended the inaugural ... Last week, the university also hosted the 4th GlobalTech ...
... and Boston, MA. Wed. July 4, 2012 One of ... treatment. In the case of many forms of cancer, including ... cancer cells in the lab, but often produce only partial, ... the field of cancer research has been and remains: how ...
... researchers have discovered that recent climate change is causing leaves ... study, which is the first of its kind in the ... in climate. The results are published online today in ... Researchers analysed leaves from herbarium specimens of Narrow-leaf Hopbush ...
Cached Biology News:Wholly water -- students and scientists gather at NTU to discuss water problem 2Wholly water -- students and scientists gather at NTU to discuss water problem 3Wholly water -- students and scientists gather at NTU to discuss water problem 4Wholly water -- students and scientists gather at NTU to discuss water problem 5Tumor microenvironment helps skin cancer cells resist drug treatment 2Tumor microenvironment helps skin cancer cells resist drug treatment 3Tumor microenvironment helps skin cancer cells resist drug treatment 4Shrinking leaves point to climate change 2
... protein A media yield highly purified ... to analysis of other immunoglobulin classes, ... purification. Protein A binds to the ... from mammalian species. This ready-to-use, bottled ...
... bis- (3-D-Gluconamidopropyl)deoxycholamide White solid. HYGROSCOPIC. ... CHAPSO. Has reduced electrostatic interactions that do ... DEAE-cellulose. Aggregation number: 8-16. Purity: ≥95% ... O. Aggregation number 8 - 16, CMC ...
Goat Anti-Horse IgG(T) Antibody, Unconjugated...
Goat polyclonal to STMN2 ( Abpromise for all tested applications). Antigen: Synthetic peptide: AKTAMAYKEK, corresponding to C terminal amino acids 2-11 of STMN2. Entrez Gene ID: 11075 Swi...
Biology Products: